Robert Babak Faryabi

faculty photo
Assistant Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
Room 553 BRB II/III, 421 Curie Boulevard
Philadelphia, PA 19104-6160
Philadelphia, PA 19104
Office: (215)573-8220
Education:
BSc (Electrical Engineering)
Sharif University of Technology, Tehran, Iran, 1995.
MSc (Electrical Engineering)
Sharif University of Technology, Tehran, Iran, 1997.
PhD (Computational Biology)
Texas A&M University, College Station, TX, 2009.
Permanent link
 

Description of Itmat Expertise

Cancer Epigenetics
Computational Biology
Genomics
Machine Learning

Description of Research Expertise

Our lab focuses on understanding the mechanism of epigenetic dysregulation in cancer. We are particularly interested in elucidating how oncogenic signals contribute to tumor pathogenicity through epigenetic misregulation, and to leverage this mechanistic understanding for improved treatments.

The lab mainly studies cancers with frequent mutations in Notch receptor families. We use combination of wet and dry techniques to understand how oncogenic Notch drives regulatory program in these tumors. Our lab benefits from various established data-rich assays and combine them with novel technologies such as chromatin conformation and single cell genomics to elucidate the mechanisms of epigenetic dysregulation in Notch-driven tumors at both population and single cell levels.

As a member of Center for Personalized Diagnostics, we are also developing computational oncology frameworks to enrich clinical significance of diagnostic tumor genomics. Our goal is to advance the paradigm of personalized medicine by leveraging big data analytics to drive correlation between the tumor genomes and clinical covariates.

To learn more about our research interests and specifics of our projects check our lab's website

Selected Publications

Schwartz GW, Manning BS, Zhou Y, Velu PD, Bigdeli A, Astles R, Lehman AW, Morrissette JJ, Perl AE, Li M, Carroll M, Faryabi RB. : Classes of ITD predict outcomes in AML patients treated with FLT3 inhibitors. Clinical Cancer Research September 2018 Notes: clincanres.0655.2018. doi: 10.1158/1078-0432.CCR-18-0655.

Schwartz G, Petrovic J, Zhou Y, Faryabi RB: Differential Integration of Transcriptome and Proteome Identifies Pan-cancer Prognostic Biomarkers. Frontiers in Genetics 9:205, June 2018 Notes: doi: 10.3389/fgene.2018.00205.

Ryan RJH*, Petrovic J*, Rausch DM, Zhou Y, Lareau C, Kluk MJ, Christie AL, Lee W, Guo B, Donohue LKH, Gillespie S, Nardi V, Hochberg EP, Blacklow SC, Weinstock DM, Faryabi RB, Bernstein BE+, Aster JC+, Pear WS+: A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Reports 21(3): 784-797, October 2017 Notes: doi: 10.1016/j.celrep.2017.09.066.

Rolland DC, Basrur V, Jeon Y-K, McNeil-Schwalm C, Fermin D, Conlon K, Zhou Y, Ng SY, Tsou C-C, Brown NA, Thomas DG, Bailey NG, Omenn GS, Nesvizhskii AI, Root DE, Weinstock DM, Faryabi RB, Lim MS, Elenitoba-Johnson KSJ: Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas. Proceedings of the National Academy of Sciences 11(24): 6581-6586, May 2017.

Barlow JH*, Faryabi RB*, Callen E, Wong N, Malhowski A, Chen H-T, Gutierrez-Cruz G, Sun H-W, McKinnon P, Wright G, Casellas R, Robbiani DF, Staudt L, Fernandez-Capetillo O, Nussenzweig A : Identification of Early Replicating Fragile Sites that Contribute to Genome Instability. Cell 152(3): 620-32, January 2013 Notes: *co-first author.

Santos MA, Faryabi RB, Ergen AV, Day AM, Malhowski A, Canela A, Onozawa M, Lee J-E, Callen E, Gutierrez-Martinez P, Chen H-T, Wong N, Finkel N, Deshpande A, Sharrow S, Rossi DJ, Ito K, Ge K, Aplan PD, Armstrong SA, Nussenzweig A: DNA-damage-induced Differentiation of Leukaemic Cells as an Anti-cancer Barrier. Nature 514(7520): 107-11, October 2014.

Callen E, Faryabi RB, Luckey M, Hao B, Daniel JA, Yang W, Sun H-W, Dressler G, Peng W, Chi H, Ge K, Krangel MS, Park J-H, Nussenzweig A: The DNA Damage- and Transcription-associated Protein Paxip1 Controls Thymocyte Development and Emigration. Immunity 37(6): 971-85, December 2012.

Faryabi RB, Vahedi G, Datta A, Chamberland J-F, Dougherty ER: Recent Advances in the Control of Markovian Gene Regulatory Networks. Current Genomics 10(7): 540-547, November 2009.

back to top
Last updated: 10/21/2018
The Trustees of the University of Pennsylvania